Association Between Opioid Dose Reduction Against Patients’ Wishes and Change in Pain Severity

Abstract

BACKGROUND: There is inadequate evidence of long-term benefit from opioid medications for chronic pain and substantial evidence of potential harms. For patients, dose reduction may be beneficial when implemented voluntarily and supported by a multidisciplinary team but experts have advised against involuntary opioid reduction. OBJECTIVES: To assess the prevalence of self-reported involuntary opioid reduction and to examine whether involuntary opioid reduction is associated with changes in pain severity. DESIGN: Prospective observational cohort study. PARTICIPANTS: Primary care patients treated with longterm opioid therapy in the Veterans Health Administration (N = 290). MAIN MEASURES: The primary exposure was selfreported past year involuntary opioid reduction. The primary outcome was the three-item PEG scale, which measures past-week average pain intensity and interference with enjoyment of life and general activity. KEY RESULTS: Past year opioid reduction or discontinuation was reported by 63% (184/290). Similar numbers reported involuntary (88/290) and voluntary (96/290) opioid reduction. At baseline, there were no significant differences in pain severity between the groups (mean PEG, 7.08 vs. 6.73 vs. 7.07 for past year involuntary opioid reduction, past year voluntary opioid reduction, and no past year opioid reduction, respectively; P = 0.32). For the primary outcome of change in pain severity from baseline to 18 months, there were no significant differences between groups (mean PEG change, − 0.05 vs. − 0.44 vs. − 0.23 for past year involuntary opioid reduction, past year voluntary opioid reduction, and no past year opioid reduction, respectively; P = 0.28). CONCLUSIONS: Self-reported past year involuntary opioid reduction was common among a national sample of veterans treated with long-term opioid therapy. Opioid dose reduction, whether involuntary or voluntary, was

Efficacy of interventions to reduce long term opioid treatment for chronic non-cancer pain: systematic review and meta-analysis

“…4 11 Opioid tapering can be complicated by the onset of withdrawal symptoms as well as increased pain, suicidality, and substance use, and such risks could increase when undertaken rapidly or without patient consent. 12 13 14 …”

Clinical and neuroscience evidence supports the critical importance of patient expectations and agency in opioid tapering

“…Most taper studies report that opioid dose can be reduced and, in some cases, discontinued without a worsening of pain. 20 However, these studies were unblinded, nonrandomized, and had no nontapered control group. Most tapering studies have not differentiated voluntary vs involuntary taper methods, although limited research comparing the 2 methods has suggested no group difference for pain intensity outcomes after taper.…”

“…Most tapering studies have not differentiated voluntary vs involuntary taper methods, although limited research comparing the 2 methods has suggested no group difference for pain intensity outcomes after taper. 20 , 28 Although seemingly promising, the authors of one of these reports 20 cautioned against an interpretation that involuntary tapering is harmless; they noted that their outcome assessment was limited and “did not evaluate potential harms of involuntary tapering such as emotional distress, disruption of the patient-clinician relationship… and rare but serious harms such as hospitalization and suicide” (severe withdrawal, overdose, and other mortality were also not quantified).…”

Opioid-sparing effects of medical cannabis or cannabinoids for chronic pain: a systematic review and meta-analysis of randomised and observational studies

“…68 Future trials should randomise chronic pain patients who voluntarily agree to engage in a trial of opioid tapering to receive medical cannabis or placebo and report all patient-important outcomes. 69 Forced opioid tapering is ineffective 70 and may cause harm. 71 …”